Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Department of Urology, Vito Fazzi Hospital, Lecce, Italy.
Int Braz J Urol. 2024 Jul-Aug;50(4):450-458. doi: 10.1590/S1677-5538.IBJU.2024.0003.
We assessed the prognostic impact of the 2012 Briganti nomogram on prostate cancer (PCa) progression in intermediate-risk (IR) patients presenting with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b treated with robot assisted radical prostatectomy eventually associated with extended pelvic lymph node dissection.
From January 2013 to December 2021, data of surgically treated IR PCa patients were retrospectively evaluated. Only patients presenting with the above-mentioned features were considered. The 2012 Briganti nomogram was assessed either as a continuous and a categorical variable (up to the median, which was detected as 6%, vs. above the median). The association with PCa progression, defined as biochemical recurrence, and/or metastatic progression, was evaluated by Cox proportional hazard regression models.
Overall, 147 patients were included. Compared to subjects with a nomogram score up to 6%, those presenting with a score above 6% were more likely to be younger, had larger/palpable tumors, presented with higher PSA, underwent tumor upgrading, harbored non-organ confined disease, and had positive surgical margins at final pathology. PCa progression, which occurred in 32 (21.7%) cases, was independently predicted by the 2012 Briganti nomogram both considered as a continuous (Hazard Ratio [HR]:1.04, 95% Confidence Interval [CI]:1.01-1.08;p=0.021), and a categorical variable (HR:2.32; 95%CI:1.11-4.87;p=0.026), even after adjustment for tumor upgrading.
In IR PCa patients with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b, the 2012 Briganti nomogram independently predicts PCa progression. In this challenging subset of patients, this tool can identify prognostic subgroups, independently by upgrading issues.
我们评估了 2012 年 Briganti 列线图对接受机器人辅助根治性前列腺切除术(RARP)治疗且最终联合扩大盆腔淋巴结清扫术的 PSA<10ng/mL、ISUP 分级 3 级和临床分期至 cT2b 的中危(IR)患者中前列腺癌(PCa)进展的预后影响,这些患者的特征为 PSA<10ng/mL、ISUP 分级 3 级和临床分期至 cT2b。
从 2013 年 1 月至 2021 年 12 月,我们回顾性评估了接受手术治疗的 IR PCa 患者的数据。仅考虑具有上述特征的患者。2012 年 Briganti 列线图被评估为连续变量和分类变量(低于中位数,中位数为 6%,高于中位数)。使用 Cox 比例风险回归模型评估与 PCa 进展(定义为生化复发和/或转移性进展)的相关性。
共纳入 147 例患者。与列线图评分低于 6%的患者相比,评分高于 6%的患者更年轻,肿瘤更大/可触及,PSA 更高,肿瘤分级升级,非器官局限性疾病,且最终病理切缘阳性。32 例(21.7%)患者发生 PCa 进展,2012 年 Briganti 列线图连续(风险比 [HR]:1.04,95%置信区间 [CI]:1.01-1.08;p=0.021)和分类变量(HR:2.32;95%CI:1.11-4.87;p=0.026)均独立预测 PCa 进展,即使在调整肿瘤分级升级后也是如此。
在 PSA<10ng/mL、ISUP 分级 3 级和临床分期至 cT2b 的 IR PCa 患者中,2012 年 Briganti 列线图独立预测 PCa 进展。在这一具有挑战性的患者亚组中,该工具可独立于升级问题识别预后亚组。